The evolution of peptidomimetic hybrid molecules for preoperative imaging and guided
surgery targeting the prostate-specific membrane antigen (PSMA) significantly progressed …

The development of PSMA-targeting low-molecular-weight hybrid molecules aims at
advancing preoperative imaging and accurate intraoperative fluorescence guidance for …

The use of an albumin binder has been shown to improve tumor uptake of prostate-specific
membrane antigen (PSMA)–targeting radiotherapeutic agents. The aim of this study was to …

The concept of using ibuprofen as an albumin-binding entity was recently demonstrated by
the development of [177Lu] Lu-Ibu-PSMA-01. In the present study, we designed a novel …

The prostate-specific membrane antigen (PSMA) has emerged as an attractive prostate
cancer associated target for radiotheragnostic application using PSMA-specific radioligands …

Resection of tumors using targeted dual-modality probes combining preoperative imaging
with intraoperative guidance is of high clinical relevance and might considerably affect the …

Resection of tumor tissue represents one of the standard curative treatment options for the
clinical management of prostate cancer [1]. However, intraoperative localization and precise …

Despite significant gains in the treatment of metastatic castration-resistant prostate cancer by
radioligands targeting prostate-specific membrane antigen (PSMA), 30% of patients never …

Prostate-specific membrane antigen (PSMA)-based low-molecular-weight agents using beta
(β)-particle-emitting radiopharmaceuticals is a new treatment paradigm for patients with …

68Ga-PSMA-11 is currently the most popular prostate-specific membrane antigen (PSMA)
radioligand used in the clinic to detect prostate cancer and metastases. However, the high …